INDP | Indaptus Therapeutics, Inc.

Index- P/E- EPS (ttm)-1.83 Insider Own2.30% Shs Outstand8.40M Perf Week-5.49%
Market Cap14.60M Forward P/E- EPS next Y-2.22 Insider Trans0.53% Shs Float5.03M Perf Month-34.10%
Income-15.20M PEG- EPS next Q-0.58 Inst Own6.90% Short Float / Ratio0.54% / 0.93 Perf Quarter0.00%
Sales- P/S- EPS this Y8.00% Inst Trans12.70% Short Interest0.03M Perf Half Y-5.56%
Book/sh2.52 P/B0.68 EPS next Y3.50% ROA-52.60% Target Price8.00 Perf Year-30.08%
Cash/sh2.56 P/C0.67 EPS next 5Y- ROE-58.60% 52W Range1.25 - 3.40 Perf YTD18.62%
Dividend- P/FCF- EPS past 5Y57.90% ROI- 52W High-49.41% Beta1.23
Dividend %- Quick Ratio12.20 Sales past 5Y- Gross Margin- 52W Low37.60% ATR0.17
Employees6 Current Ratio12.20 Sales Q/Q- Oper. Margin- RSI (14)37.65 Volatility9.16% 8.79%
OptionableNo Debt/Eq0.00 EPS Q/Q-24.20% Profit Margin- Rel Volume0.29 Prev Close1.74
ShortableYes LT Debt/Eq0.00 EarningsMar 17 BMO Payout- Avg Volume28.96K Price1.72
Recom2.00 SMA20-15.21% SMA50-18.32% SMA200-12.40% Volume8,315 Change-1.15%
May-31-23 08:30AM
May-11-23 07:00AM
May-09-23 08:00AM
May-01-23 08:00AM
Apr-24-23 09:00AM
04:05PM Loading…
Apr-20-23 04:05PM
Apr-19-23 09:28AM
08:05AM
Apr-17-23 08:00AM
Mar-22-23 08:00AM
Mar-17-23 08:00AM
Mar-15-23 08:05AM
Mar-13-23 08:05AM
Mar-07-23 08:05AM
Feb-14-23 08:00AM
08:05AM Loading…
Feb-07-23 08:05AM
Dec-13-22 07:30AM
Nov-10-22 04:05PM
Oct-18-22 07:00AM
Sep-06-22 09:02AM
Aug-08-22 08:00AM
Jun-09-22 07:00AM
Jun-03-22 07:00AM
May-23-22 08:00AM
May-19-22 07:00AM
May-18-22 04:15PM
May-12-22 08:00AM
May-03-22 12:20PM
Apr-20-22 07:00AM
Mar-23-22 07:00AM
07:00AM Loading…
Mar-21-22 07:00AM
Mar-17-22 07:00AM
Mar-07-22 07:00AM
Jan-14-22 09:38AM
Jan-05-22 07:00AM
Jan-03-22 07:00AM
Dec-01-21 08:00AM
Nov-15-21 07:00AM
Nov-04-21 10:51AM
Sep-15-21 07:00AM
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Litchev Boyan VesselinovChief Medical OfficerDec 01Buy1.875009351,150Dec 19 09:06 PM
Litchev Boyan VesselinovChief Medical OfficerNov 22Buy1.83500915650Dec 19 09:06 PM
Meckler Jeffrey ACEO and DirectorNov 21Buy1.909,60018,24075,374Nov 22 08:00 AM
Meckler Jeffrey ACEO and DirectorNov 18Buy1.7640070565,774Nov 22 08:00 AM
Meckler Jeffrey ACEO and DirectorSep 08Buy2.8010,30828,86265,374Sep 12 09:00 AM
Meckler Jeffrey ACEO and DirectorSep 07Buy2.578,63222,18455,066Sep 08 09:00 AM
Linscott Walt AddisonChief Business OfficerSep 07Buy2.62150393150Sep 09 09:00 AM
Meckler Jeffrey ACEO and DirectorSep 06Buy2.441,0602,58646,434Sep 08 09:00 AM
Meckler Jeffrey ACEO and DirectorJun 06Buy2.6319,72751,88245,374Jun 07 08:00 AM